Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer
2021; BMJ; Volume: 9; Issue: 3 Linguagem: Inglês
10.1136/jitc-2020-002084
ISSN2051-1426
AutoresColt A. Egelston, Weihua Guo, Susan E. Yost, Jin Sun Lee, D. L. ROSE, Christian Avalos, Jian Ye, Paul Frankel, Daniel Schmolze, James Waisman, Peter Lee, Yuan Yuan,
Tópico(s)Lung Cancer Research Studies
ResumoSingle-agent pembrolizumab treatment of hormone receptor-positive metastatic breast cancer (MBC) has demonstrated modest clinical responses. Little is known about potential biomarkers or mechanisms of response to immune checkpoint inhibitors (ICIs) in patients with HR+ MBC. The present study presents novel immune correlates of clinical responses to combined treatment with CDK4/6i and ICI.
Referência(s)